Veloxis wins popularity among newly transplanted patients: "We're way ahead of what we had anticipated"
15.5 percent of all US kidney transplant patients now receive treatment with Veloxis' drug Envarsus to prevent organ rejection. This is far more than the company dared to hope for when the drug was approved for de novo patients in December.
Just eight months ago, Veloxis got its 'de novo' approval with the FDA, allowing the prescription of the company's organ rejection prophylaxis drug Envarsus for de novo kidney transplant patients.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
